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1. Introduction 
There are many types of cancer, some occurring 
commonly and others which are very rare. Different 
cancers can be distinghuished from one another because 
of differences in their morphology and natural history, 
in their cell kinetic and biochemical properties and from 
their response to chemotherapy. 
At one time, chemotherapy was used primarily in 
the treatment of leukaemias and lymphomas, and in a 
few other types of cancer such as choriocarcinoma [l] . 
More recently it has been shown that chemotherapy 
given immediately after surgery or radiotherapy (termed 
adjuvant chemotherapy) has significantly increased the 
proportion of long-term survivors in other types of 
cancer and is currently being tested in many more. 
Preliminary results using simple (one drug) adjuvant 
chemotherapy of breast cancer, a very common cancer, 
has indicated that a significant reduction in recurrence 
of the cancer may be obtained if the drug is given soon 
after surgery [2]. Since a substantial proportion (30%) 
of operable breast cancers recur after surgery, small 
deposits of tumour must have been left behind in many 
cases, usually as metastases at a distance from the 
primary tumour. The aim of adjuvant chemotherapy 
is to treat the metastases when they consist of only a 
small number of cells, at which time they are most 
susceptible to chemotherapy. 
Progress in cancer chemotherapy isrelatively slow, 
but once a cancer is known to be sensitive to one or 
more chemotherapeutic agents, results usually get 
progressively better as the optimal conditions for 
chemotherapy are worked out by clinical trials. In 
1960, for example, although the first anti-cancer agents 
had been discovered and were undergoing clinical 
evaluation, survival from acute lymphoblastic leukaemia 
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of childhood was measured in terms of months. In 1967, 
the proportion of childkn (in the United States) treat- 
ed by chemotherapy and surviving longer than five 
years without recurrence of the disease was 25%, and 
by 1972, this proportion had risen to 50%. Since it is 
expected that most patients will never elapse after 
having been free from tumour for five years, then it is 
clear that a cancer which was incurable 15 years ago 
can now be successfully treated by chemotherapy in
a large proportion of cases. 
Advances in chemotherapy have been made by the 
discovery of new classes of anti-cancer agents [3], by 
the use of drug combinations [4], and by learning more 
about the cell kinetic and biochemical properties of 
tumours and the way in which they differ from normal 
tissues [5,6]. This article is restricted to a description 
of the types of chemical that have anti-cancer activity 
and the ways in which attempts are made to improve 
upon their selectivity. 
2. Cytotoxic agents 
Anti-cancer agents used today are not specifically 
toxic for cancer cells in the same way that the sulphon- 
amides, for example, are selectively toxic for bacteria. 
The basic property of anti-cancer agents in their ability 
to kill dividing cells in general and thus they can prevent 
tumour growth but only at a cost to normal dividing 
tissues uch as bone marrow and mucosal surfaces. For 
this reason anti-cancer agents are referred to as cytotoxic 
agents but under certain conditions complete tumour 
cell destruction can be achieved at dose levels which 
do not cause unacceptable toxicity. 
Anti-cancer agents may be classified according to 
the stage of the cell cycle at which they act or, more 
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usually, according to their chemical structure and 
mechanism of action. By the latter classification, there 
are (a) a large class of electrophilic reactants, (b) the 
anti-tumour antibiotics, (c) the antimetabolites, partic- 
ularly the anti-folates and the purine and pyrimidine 
antagonists, and (d) a variety of cheinicals which arrest 
cells in mitosis and are referred to as the spindle 
poisons. In addition, there are several agents which do 
not belong to any of these classes. 
3. Electrophilic reactants 
3.1. Bifunctional alkylating agents 
The aliphatic nitrogen mustard HN2 (I) was one of 
the first anti-cancer agents to be used effectively in the 
clinic and since that time many more related alkylating 
agents have been studied. Clinically usuful compounds 
include the aromatic nitrogen mustard, melphalan (II), 
the bisulphonoxyalkane myleran (III), and the ethylene- 
imide, thioTEPA (Iv). All act in a similar way by alkyl- 
ation of nucleophilic sites in cells, for example ionised 
acidic and thiol groups and uncharged amine groups 
of nucleic acids and proteins. Usually the alkylating 
agents act by an S,2 mechanism, involving the forma- 
tion of an intermediate transition complex, but the 
less basic aromatic nitrogen mustards can act by an 
S, 1 mechanism, where the rate-limiting step is ionisa- 
tion to form a carbonium ion. The bifunctional alkyl- 
ating agents all have similar distinctive biological pro- 
perties. Since a tumour sensitive to one alkylating agent 
is likely to be sensitive to another, and because tumours 
with acquired resistance to one alkylating agent are 
CHy3i2CI 
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cross-resistant to all others, it is assumed that all bifunc- 
tional alkylating agents act by a similar mechanism. The 
absolute requirement for at least two alkylating enti- 
ties in the molecule suggested that the cytotoxicity of 
the alkylating agents was due to a cross-linking reaction 
involving alkylation of two nucleophilic entres in the 
same or different molecules. Because the alkylating 
agents react with many biological molecules, it has 
proved difficult to determine the exact mechanism by 
which they kill cells. The best hypothesis at present is 
that the most sensitive site in the cell, dkylation of 
which leads to toxicity, is DNA and that some form of 
inter- or intra-strand cross-linking takes place. In parti- 
cular situations, however, it has been claimed that 
glycolytic pathways, cell membranes, nucleoprotein 
and CAMP phosphodiesterase r all essential target 
sites for the alkylating agents. 
Although it is likely that all alkylating agents act in 
the same way, some may be more effective than others 
as anti-cancer agents. Whether or not a drug will be 
active against aparticular cater will depend on the 
balance between the damage caused to the cancer and 
the damage to normal tissues. The biochemical and 
cell kinetic properties of a cancer, as well as its location 
in the body and its blood supply, are just some of the 
features which will determine its sensitivity to chemo- 
therapy. The tissue distribution of a drug, its biologi- 
cal and chemical half-life, its differential metabolism 
in normal and tumour cell, and whether any damage 
it causes can be repaired, are all factors regulating the 
degree of anti-tumour effect attainable under optimal 
conditions. 
3.2. Mechanisms of selectivity 
Alkylating agents usually enter cells by passive 
diffusion, but HN2 [l] is actively transported by some 
cells utilising the choline transfer system [7], which 
may explain why it is the preferred alkylating agent in 
the treatment of some forms of cancer. 
Agents have also been designed whose chemical 
half-lives are extremely short [8]. These are injected 
directly into the blood vessels supplying the turn&r, 
which is therefore xposed to a high concentration of 
alkylating agent. Most of the alkylating agent escaping 
from the tumour will have reacted before it reaches the 
bone marrow. This approach as had some success in 
the treatment of head and neck cancer, but where 
tumours are localised and readily accessible they are 
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usually better dealt with by surgery or radiotherapy. 
Enzymes that occur in very high concentration i  
cancer cells can also be the basis for the design of selec- 
tive agents. Thus, primary liver cancer has a high level 
of azo-reductase which can convert a noncytotoxic 
azo-mustard (V) into a chemically reactive and highly 
cytotoxic amine (VI) whose half-life is so short that 
any of it that leaves the liver will have reacted harm- 
lessly in the extracellular fluids or have been hydrolys- 
ed (VII) before reaching the bone marrow [9] There 
will also be a high live1 of alkylation of normal iver 
cells but these are mostly non-dividing and non-sensitive 
to alkylation. A similar approach uses aniline mustard 
which is converted to its para-0glucuronide in liver 
and then hydrolysed to the highly toxic para-hydroxya- 
niline mustard in tumour cells with exceptionally high 
glucuronidase l vels. Unfortunately, although particular 
animal tumours may be found to have abnormally high 
levels of an enzyme, it does not follow that there will 
be human tumours with similarly high levels of the 
same enzyme. A significant advance in this field has 
been the demonstration that human tumours can be 
grown in mice whose immunological responses are de- 
pressed genetically (‘nude’ athymic mice) or artifically 
(T lymphocyte-deprived mice) [lo] . As these tumour 
(VI) (VII) 
models begin to be used in experimental chemotherapy, 
they may be found to have unusual concentrations of
enzymes which may be characteristic of a particular 
type of human cancer and thus provide the basis for 
rational chemotherapy. 
The absence of enzymes in cancer cells may also 
make them susceptible to chemotherapy. Cyclophos- 
phamide (VIII) is, in many cases, abetter anti-cancer 
agent han related nitrogen mustards. Although acting 
by the same mechanism, cyclophosamide is highly 
selective, probably because it is hydroxylated in the 
liver to 4-hydroxycyclophosphamide, which is in 
equilibrium with its tautomeric aldehyde (aldophospha- 
mide; IX). Neither (VIII) nor (IX) are chemically reac- 
tive and the latter can be converted by aldehyde dehy- 
drogenases to the propionic acid (X) which is also non- 
cytotoxic. In the absence of any enzymes, however, 
(IX) can undergo a chemical &elimination to form phos- 
phoramide mustard (XI) and acrolein (XII), both of 
which are cytotoxic. It has been suggested that the 
higher selectivity of cycle phosphamide compared with 
other alkylating agents can be accounted for by the 
greater breakdown of aldophosphamide in tumour cells 
to phosphoramide mustard because of their lower levels 
of dehydrogenase enzymes [11 ,121. 
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3.2, Other electrophilic reactants agents in its mechanism of action. It can, for example, 
Dimethyltriazenoimidazole carboxamide (DIC; cause complete regression of animal tumours which are 
XIII) is believed to act by some form of alkylation, resistant to alk!lating agents. Inactive in its own right, 
but it is clearly different from bifunctional alkylating DIC is metabolised by liver microsomes to the mono- 
methyl derivative (XIV) which can react directly with 
(1 
” I 
CONH2 
a 
CONH2 
/ I 
nucleophiles or which can break down to alkylating 
H N=N-N(CH3$ 
(XIII) 
HN 
fragments such as methyl carbonium ions. One of the 
N=N-NH.CH3 problems associated with the clinical use of DIC is that 
WW it causes erious nausea nd vomiting. Since it can break 
Table 1 
Activation of phenyltriazenes. Only those alkytriazenes that are metabolised 
by liver microsomes in vitro to 3-N-methylphenyltriazene have activity 
against he mouse TLXS transplanted lymphoma. Alkyltriazenes that do not 
form this metabolite are inactive, despite the fact that they can also break 
down to alkylating moieties. 
Agent 
en3 
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R.NH.CH3 
Cn3 
(XXI) 
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down by photochemical reaction to a diazonium com- 
pound which is higly toxic and could be the cause of 
the side effects, a series of phenyltriazenes which are 
light stable, have also been investigated [ 131. Table 1 
shows the structure activity relationship of this series. 
Only chemicals that can be converted enzymatically 
to phenyl methyltriazene have antitumour properties. 
Thus the methylethyl analogue (XV) is active because 
de-ethylation ispreferred to demethylation and the 
active monomethyltriazene is formed. Although the 
diethyl analogue (XVI) is dealkylated as readily as the 
dimethyl analogue (XVII), it is clearly inactive. The 
mixed methylalkyltriazenes (XIX and XX) are both 
active and, since no demethylation could be detected 
on incubation with microsomes, it was assumed that 
the higher alkyl group was being removed. This cannot 
occur with the tertiary isobutylmethylphenyltriazene 
(XXI) since the higher alkyl group has no o-hydrogen 
and this compound is readily demethylated by liver 
microsomes. In this case, the tertiary monoisobutylphen- 
yltriazene is formed and (XXI) is, as expected, not 
active as an anti-tumour agent. The selective anti-tumour 
effect of monomethyltriazenes compared to higher alkyl 
derivatives has not yet been explained, but it is possible 
that, if they are electrophilic reactants in their own 
right, their essential target site in the tumour cell is 
sterically hindered and only accesible to monomethyl- 
triazenes. 
A requirement for an N-methyl rather than an N- 
ethyl or higher alkyl group is also seen with procarba- 
zine (natulan; XXII). I.&e the triazenes, procarbazine 
is not active itself, but decomposes invivo into as yet 
unidentified anti-tumour agents [14,151. 
Another N-methyl derivative which has anti-cancer 
activity is hexamethylmelamine (HMM; XXIII). 
Although almost rejected because of its minimal activi- 
ty against animal tumours, HMM has significant activi- 
ty in man, particularly in the treatment of lung and 
ovarian cancer. It is also highly active against human 
tumours transplanted into immunologically-deprived 
mice, especially lung [ 161 and kidney tumours, but 
also against tumours of the ovary and colon. Little is 
B 
CH3.N.C.NH.J CI.CH3CH3~ & .NH R 
ILO NO 
(XXIV) (XXV 1 
BCNU R = CH3CH3CI 
CCNU R= 0 
MaCCNU R= 
u 
CH3 
known of the mode of action of HMM, but it is remi- 
niscent of the triazenes in that small changes in struc- 
ture can lead to complete loss of activity (Table 2). 
There is an apparent correlation between demethyla- 
tion and anti-cancer activity (Table 2) and this has led 
to the suggestion that it is an intermediate methyl01 
which may be the active metabolite. N-Methylols have 
been postulated as cross-linking agents responsible for 
the mutagenicity of formaldehyde [17] . 
Methylnitrosourea (XXIV), although a potent carci- 
nogen, is also used in the treatment of lung cancer. 
Its anti-tumour properties were first demonstrated many 
years ago and a series of related chloroethylnitrosour- 
eas based on this structure have since been used clini- 
cally (BCNU, CCNU, MeCCNU; XXV). They decom- 
pose rapidly under physiological conditions, to a number 
of carbamoylating and alkylating products as well as 
aldehydes or alcohols [181. Cytotoxicity may be the com- 
bined result of a variety of reactions, e.g. interferences 
with the function of DNA by alkylation and inhibition of 
DNA alkylation repair enzymes by carbomoylation. No 
explanation can yet be given for their selective anti-tumour 
effects which, in the case of some animal tumours, is 
quite remarkable. For instance, the TLXS lymphoma, 
in CBA&AC mice, grows from a single cell. After injec- 
tion of lo6 cells, there is a rapid spread of tumour and 
about 9 days later the mice die, at which time tumour 
cells can be found in most body organs. BCNU is so 
selective that tumour-bearing animals can still be treated 
on day 8 and a proportion of them cured. 
(CH3)2.CH.NHC0 CH2NH.NH.CH3 
(C H&N (CH312 
(XXII) (XXIII) 
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Table 2 
Structure activity relationships of a series of N-substituted melamines. Only 
compounds that are demethylated by liver microsomes in vitro have activity 
against he mouse plasma cell tumour. (Expressed as a therapeutic index). 
The more readily a derivative is demethylated the higher is its therapeutic 
index. 
Agent 
H2N 
NHCH3 
A N/ N 
NH2 
t$tCH3 
NHCH3 
N(C3 H& 
N/ N 
K2H512Nfi ‘N 
I 
N(C2H& 
Demethylation by 
m icrosomes 
Antitumour 
activity 
+++ 10.3 
1.8 
Inactive 
Inactive 
Inactive 
Inactive 
October 1975 
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4. Platinum co-ordination complexes 
Closely related platinum complexes vary widely in 
their anti-cancer properties. Thus cis-dichlorodiammine 
platinum(I1) (Cis Pt(I1); XXVI), isolated as one of the 
stable bacteriostatic products formed when an electri- 
cal current was passed through a medium in which 
bacteria were growing, has a wide spectrum of action 
against animal tumours. However. the frans analogue 
(XXVII) is inactive and platinum cannot generally be 
“““a/” H3N\pd/C’ 
Cl ’ ‘NH 3 H$/ 'Cl 
replaced by other heavy metals uch as palladium 
(XXVIII), although recently a few rhodium, iridium 
and palladium complexes have been shown to have 
anti-cancer activity [ 191. Even in a homologous eries, 
the selectivity of the compounds can vary considerably 
either by alteration of the tumour inhibitory dose or 
the lethal dose (Table 3). However, whether a com- 
pound is better than a related analogue is a property 
not only of the drug but of the tumour used to assess 
activity. The L1210 leukaemia (Table 3) appears to be 
particularly responsive to hydrophilic derivatives and 
the plasma cell tumour to lipophilic ones. 
In many of their biological properties, the platinum 
complexes resemble the bifunctional alkylating agents, 
and they probably act similarly by cross-linking DNA. 
In this case, the most probable cross-linking site involves 
Table 3 
The effect of a series of platinum compounds against he mouse plasma cell tumour (PC6) 
and L1210 leukaemia (L1210). With increasing size of the alicyclic ring the therapeutic index (TI) 
against he plasma cell tumour increases. Conversely, the effect against he L1210 leukaemia, 
expressed as the maximum increase in life span (%ILS) at the optimum dose, decreases with 
increasing size of the alicyclic ring. PC, octanol water partition coefficient. Water solubility 
expressed as mg/litre. 
Agent 
SOI. 
PC6 (1. I.1 L 1210 (2 I.L.S.) water PC 
NH3 
‘pt’ 
Cl 
NH< ‘CI 
8.1 95 2,650 (01 
24-6 
u 
\pt’ 31.0 
NH’ ‘Cl 2 
>267 3 1.9 4. 3 
70 610 co1 
52 07 .05 
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the amino groups of adenosine residues, especially 
where they lie one above the other in the same strand 
[ 191. Despite this similarity, Cis pt(I1) (XXVI) is active 
in the clinic against cancers of the ovary that have ac- 
quired resistance to alkylating agents. 
5. Anti-tumour antibiotics 
As a result of screening extracts of soil micro-orga- 
nisms, many different classes of antibiotics have been 
shown to have anti-cancer properties. This usually 
means they are toxic to cancer cells in culture or have 
some effects on the growth of transplanted animal 
tumours and does not necessarily mean they are useful 
in man. In practice, only actinomycin [20], daunomy- 
tin, adriamycin and bleomycin [21] are used in the 
clinic to any great extent. Bleomycin, which is a mix- 
ture of related compounds, has a particular affinity for 
squamous cell carcinoma nd etpihelial tissues in gene- 
ral. Thus, the antibiotic can inhibit squanous cell carci- 
noma in mice induced by 20.methylcholanthrene but
does not inhibit’sarcoma induced in mouse skin by the 
same chemical. This tissue selectivity is in part due to 
the selective concentrati& of bleomycin by epithelial 
tissues (and lung) and in part due to their lowered 
ability compared to other tissues to convert he anti- 
biotic enzymatically to a non-cytotoxic form. In con- 
trast, daunomycin is reduced enzymatically to daunt- 
mycinol, which is probably a more selective anti-tumour 
agent, since anti-tumour effectiveness has been correlat- 
ed. with the levels of-the reductase nzyme. 
Bleomycin, probably because it is a mixture of pro- 
ducts, has a variety of actions causing single-strand 
breaks of DNA, inhibition of DNA-dependent DNA 
polymerase and arrest of cells just prior to mitosis. 
Adriamycin, daunomycin and actinomycin act by 
some form of intercalation, amolecule of the antibio- 
tic inserting between stacked base pairs of the double 
helix, interfering-with replication and transcription. 
Adriamycin is of particular interest because it has acti- 
vity against solid turnours, but because it causes 
cardiac toxicity there are many clinical situations 
where it cannot be used. Its structural relationship to 
the cardiac glycosides has been suggested as the reason 
for its specific effects on cardiac muscle, and attempts 
are at present being made to design derivatives which 
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I 
Daunorubicin Complex 
I (Endocytosis) w 
1 (Formation of Phagosomej 
active drug) 
Intercalation 
with Nuclear DNA 
Fig.!. Use of stable DNA-Daunorubicin (or adriamycin) com- 
plexes to increase selectivity. Concentration of the complex 
inside tumour cells may occur by endocytosis. The resultant 
phagosome can condense with a lysosome and release_ active 
antibiotic inside the cytoplasm of the tumour cell. After 
Trouet et al. [ 221. 
are less related in chemical structure to the digitalis 
glycosides. 
In further attempts to improve the selectivity of 
adriamycin and daunomycin the antibiotics have been 
intercalated with fragments of DNA in vitro. The re- 
sulting complexes are stable and non-toxic, but could 
give selectivity by the scheme of fig. 1. Tumour cells 
are known to take up high molecular weight materials 
by endocytosis and thus they may, unlike cardiac 
muscle.cells, concentrate a significant amount of the 
antibiotic-DNA complex. Once inside the cells (in the 
structure of a phagosome j condensation with a lysosome 
takes place and the complex is exposed to DNAase. 
This releases the antibiotic in its cytotoxic form inside 
the tumour cell’ [22]. These complexes are more selec- 
tive anti-tumour agents than the antibiotic alone under 
optimal aboratory conditions, and they are at present 
on clinical trial. 
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Related attempts to deliver cytotoxic drugs peciti- 
tally to tumours involve attachment of cytotoxic 
groups to tumour ‘specific’ proteins which will concen- 
trate in the area of the tumour [23] and incorporation 
of the drug into liposomes, which like the DNA com- 
plexes may be selectively endocytosed by tumour cells 
[241- 
6. Antimetabolites 
Clinically useful antimetabolites are antagonists of
folic acid (e.g. methotrexate, XXIX) of purines (e.g. 
6 mercaptopurine; XXX) or pyrimidmes (e.g. cytosine 
arabinoside; XXXI. By definition, these agents ubsti- 
tute for normal metabolites in various biochemical 
pathways and their cytotoxicity is greatly influenced 
by the levels of natural meatbolites with which they 
are competing. Thus the cytotoxicity of methotrexate 
can be reversed by folinic acid (which bypasses the site 
of methotrexate inhibition) or by thymidine (the ma- 
jor effect of methotrexate on dividing cells is to cause 
a lack of thymidylate). By carefully varying the time 
at which cells are ‘rescued’ from the cytotoxicity of 
antifolates, an optimum situation can be found where 
normal tissues can be rescued but at a time when can- 
cer cells are already irreversibly inhibited [25]. Large 
numbers of new types of anti-metabolite have been in- 
CH, 
(y&COOH 
O.NH.CH.COOH 
(XXXI) 
NH 
(XXXII) (XXXIII) 
vestigated and a new one of interest is 5-azacytidine 
@XXII) which is not cross-resistant to cytosine arabi- 
noside in patients with acute granulocytic leukaemia. 
Cytosine arabinoside islimited in its clinical use because 
it must be maintained at a physiologically effective 
dose in the body for the period of time that it takes all 
cancer cells to enter the phase of the cell cycle (DNA 
synthesis) which is sensitive to the drug. Because cyto- 
sine arabinoside israpidly broken down by cytidine 
deaminase in the liver and other organs, these levels can 
only be maintained by infusion. More stable derivatives 
acting in the same way are currently being investigated, 
such as cyclocytidine (XXXIII), which has a long bio- 
logical half-life and slowly hydrolyses to cytosine ara- 
binoside [26]. A novel approach as been to synthesis 
transtion state analogues [27]. Thus carbamyl aspar- 
tate is synthesised from aspartate and carbamyl phos- 
phate via a proposed transition state shown in fig.2. 
e 
HOOC - CH,-CH-NH, 
hOH 
+ 
NH,-C-O-P-O- 
6 ;_ 
, 
;HOOC 
I 
I 
HOOC -CHz -FH-NH, 
COOH F; 
/NH1 
Carbarfryl as&t* 
! 
HCGC-CHs-CH -NH CK -p-o- 
&OH 
\/ ;_ 
b: 
FaA 
Fig.2. Design of transition state analogues. The antimetabolite 
(PALA) resembles in chemical structure the proposed transi- 
tion state occurring during the enzymatic condensation of aspar- 
tate and carbamyl phosphate to form carbamyl aspartate (after 
Swyryd et al. [27]). 
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N-Phosphonoacetyl-L-aspartate (PALA) is an analogue 
of this proposed transition state and it has been shown 
to be a good inhibitor of pyrimidine biosynthesis. 
pyrirnidine biosynthesis. 
6. Spindle poisons and enzymes 
A number of chemicals that have the ability to arrest 
cells in metaphase apparently do so by condensing 
with the microtubular protein vital for the formation 
of the spindle apparatus. As a result cells are arrested 
in metaphase [28]. Only two compounds, vinblastine 
and vincristine, are selective nough to be used in can- 
cer chemotherapy. Despite their structural similarity, 
they are different in many of their biological proper- 
ties, which is probably accounted for by cells being 
differentially permeable to the two chemicals. 
Asparaginase is remarkably effective against animal 
tumours which do not have the asparagine synthetase 
enzyme and which rely on extracellular fluid as their 
sole source of asparagine. Unfortunately, not many 
human tumours are lacking the synthetase nzyme and 
those that do often quickly acquire resistance, with the 
result hat asparaginase i  used only in the treatment 
of acute leukaemia. Attempts to find other enzymes 
with anti-tumour activity in vivo have not been success- 
ful. Some, like glutaminase, can kill tumour cells in 
vitro, but glutaminase, unlike asparaginase, is very toxic 
to whole animals. An interesting finding has been that 
although the growth of both normal and tumour cells 
in vitro is inhibited by lack of methionine, normal 
cells can utilise tetrahydrofolate and homocystine in 
place of methionine, but tumour cells cannot do so. 
This suggests hat some or all cancers may have a greater 
dependence on preformed methionine than normal 
iissues and suggests hat a methioninase may be a selec- 
tive anti-tumour agent [29]. 
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